Beam Therapeutics Inc

Company Profile

• Business description

  Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

• Contact

  238 Main Street
  CambridgeMA02142
  USA

  T: +1 857 327-8775

  E: [email protected]

  https://www.beamtx.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  522